In June 2024, the prestigious Congenital, Structural and Valvular Interventions (CSI Frankfurt 2024) conference was held in Frankfurt, Germany. Professor Xie Yongquan from Fuwai Hospital, Chinese Academy of Medical Sciences, was invited to Germany to present at the Device Innovation Competition. He shared the successful completion of China's first multicenter clinical trial case using the HaloStitch® Transcatheter Patent Foramen Ovale (PFO) Suturing System, independently developed by Conmind Medical, a subsidiary of Juxin Medical, under zero-radiation pure ultrasound guidance for patent foramen ovale (PFO) closure. This demonstration of Chinese wisdom, Chinese strength, and Chinese solutions captivated the international stage, earning full recognition and high praise from attending experts. Conmind Medical was awarded second place in the Innovation Competition (CSI START-UP AWARD) for the development journey of the HaloStitch® Transcatheter Patent Foramen Ovale Suturing System and its inaugural application in China's multicenter clinical trial.

The HaloStitch® Transcatheter Patent Foramen Ovale Suturing System represents an innovative medical technology and is China's first system capable of closing PFO through suturing via femoral venous access.

Compared to traditional surgical methods, the HaloStitch® Transcatheter Patent Foramen Ovale Suturing System offers reduced surgical trauma and shorter recovery times, significantly alleviating patient suffering and discomfort. Unlike existing occluder devices, the HaloStitch® suturing system is manufactured from medical-grade polymer materials with no metallic implants, eliminating nickel ion release that could cause allergic reactions and MRI risks, fundamentally avoiding problems associated with occluders such as poor wall apposition, displacement/dislodgement, friction with intracardiac tissues, atrial perforation, effects on adjacent tissues, and incomplete endothelialization. This approach also prevents postoperative complications including cardiac perforation, cardiac tamponade, pericardial effusion, and arrhythmias. The system eliminates thrombus formation, eliminates the need for long-term anticoagulation therapy, does not obstruct the atrial septum, does not interfere with electrophysiological conduction, and preserves the possibility for future transseptal access procedures.

Currently, multiple centers nationwide have simultaneously initiated clinical enrollment. We anticipate that in the near future, the HaloStitch® Transcatheter Patent Foramen Ovale Suturing System will, through widespread adoption by more centers and clinical operators, pioneer and lead a revolutionary new approach to PFO closure procedures.